S1706 (Just in Time trial. See Notes)
This phase II trial studies how well radiation therapy with or without olaparib works in treating patients with inflammatory breast cancer. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether radiation therapy with or without olaparib may work better in treating patients with inflammatory breast cancer.
This is a "Just in Time" study. That means that it will take 7-10 days before IRB approval and consent form are available for use. Please contact the CRA so that the process can begin as soon as possible prior to the time the consent needs to be presented.
- MBMC, Chris Sanders, 314-996-5802
View More Information - This link will take you to clinicaltrials.gov for specific study information including eligibility criteria. A full list of participating institutions can also be found on this page.